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Striking Similarities in Systemic Factors
Contributing to Decreased Exercise
Capacity in Patients With Severe
Chronic Heart Failure or COPD*
Harry R. Gosker, MSc; Nicole H. M. K. Lencer, MD; Frits M. E. Franssen, MD;
Ger J. van der Vusse, PhD; Emiel F. M. Wouters, PhD, FCCP; and
Annemie M. W. J. Schols, PhD
Aims: Chronic heart failure (CHF) and COPD are both characterized by muscular impairment.
To assess whether the severity and functional consequences of muscular impairment are disease
specific, we compared skeletal muscle function, body composition, and daily activity level relative
to exercise capacity between these two disorders.
Methods: Twenty-five patients with CHF and 25 patients with COPD, and 36 healthy gender- and
age-matched control subjects underwent measurement of fat-free mass (FFM) [by bioelectrical
impedance analysis] as an index of muscle mass. Quadriceps and biceps functions were tested by
isokinetic methods, and daily activity level was assessed by the Physical Activity Scale for Elderly
(PASE) questionnaire. Peak oxygen consumption (V̇O2peak) was measured by incremental cycle
ergometry.
Results: PASE results were similar in patients with CHF and in patients with COPD, each group
scoring lower than control subjects. FFM was also lower in patients than control subjects and
correlated closely with quadriceps and biceps strength in all three subgroups, R values ranging
from 0.63 to 0.78, with identical slopes. FFM also correlated significantly with V̇O2peak
(p < 0.05), but slopes were less steep in patients than in control subjects. The type and severity
of muscle dysfunction were similar in each group of patients. There were no significant
correlations between indexes of cardiopulmonary function and muscle function or exercise
performance in patients with CHF or in patients with COPD. In both control subjects and
patients, FFM was the most significant determinant of V̇O2peak.
Conclusion: Muscle dysfunction is not limited to the lower limbs, but generalized and comparable
between patients with CHF and patients with COPD with similar exercise capacity. FFM is a
strong predictor of peripheral muscle strength, to a lesser extent of V̇O2peak, and not at all of
peripheral muscle endurance. (CHEST 2003; 123:1416–1424)
Key words: chronic heart failure; COPD; daily activity level; exercise capacity; fat-free mass; isokinetic muscle function
Abbreviations: BMI  body mass index; CHF  chronic heart failure; Dlco  diffusion capacity of the lung for
carbon monoxide; FFM  fat-free mass; FFMI  fat-free mass index; HR  heart rate; LVEF  left ventricular
ejection fraction; Nm  newton-meter; PASE  Physical Activity Scale for the Elderly; RQ  respiratory quotient;
V̇co2peak  peak carbon dioxide production; V̇e  minute ventilation; V̇o2peak  peak oxygen consumption
E xercise intolerance is an important symptom inchronic heart failure (CHF) and COPD that
exerts a large impact on the quality of life of patients
with these disorders.1 Generally, research and ther-
apy primarily focus on cardiac dysfunction in CHF,
reflected by a reduced left ventricular ejection frac-
tion (LVEF), and on lung dysfunction in COPD,
reflected by a reduced FEV1; however, these indexes
of primary organ failure are poor predictors of exercise
capacity in moderate-to-severe disease,2,3 in particular
in patients with significant exercise intolerance.
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Muscle wasting and weakness, two potential de-
terminants of reduced exercise capacity, have been
demonstrated in both COPD and CHF. Anker et al4
showed reduced muscle strength in cachectic (de-
fined as  7% involuntary weight loss) compared to
noncachectic patients with CHF. We recently dem-
onstrated that fat-free mass (FFM), an indirect
measure of muscle mass, is a strong predictor of
muscle strength in COPD.5 Since FFM is the met-
abolically active and oxygen-consuming tissue mass,
comprised mainly of muscle tissue, it is also likely to
be a determinant of exercise capacity. A positive
relationship between muscle function and exercise
capacity, as previously shown in both COPD6 and
CHF,7 might therefore indirectly reflect a relation-
ship with FFM. Muscle function is largely charac-
terized by strength and endurance. Strength is de-
fined as the capacity of the muscle to develop
maximal force, while endurance is the capacity of the
muscle to maintain a certain force to resist fatigue.
Loss of either one of these components results in
muscle weakness and impaired muscle performance.
The relative contribution of strength and endurance
to exercise capacity in COPD and CHF remains
unknown. Furthermore, it is unclear whether muscle
weakness is generalized or predominantly affects the
lower extremities.6–8 Patients with CHF and patients
with COPD have reduced daily activity levels, and it
is therefore likely that deconditioning itself adversely
affects their exercise capacity, by definition. The
relative contributions of muscle function, FFM, and
daily activity level to exercise capacity have not been
studied in CHF or in COPD. Furthermore, no study
has yet made a direct comparison between the two
patient groups.
Therefore, the first objective of the present study
was to establish if muscle function, FFM, and daily
activity level are similarly reduced in patients with
CHF and patients with COPD and to what extent
these factors are determinants of exercise capacity.
The second objective of this study was to examine
whether impaired peripheral muscle strength and
endurance affects upper and lower limbs in patients
with CHF and patients with COPD. For these
purposes, we carefully assessed cardiac and pulmo-
nary function, body composition, peripheral muscle
function, and daily activity level in patients with




Groups of 25 patients with COPD with moderate-to-severe
airflow obstruction, 25 patients with moderate-to-severe CHF,
and 36 healthy age-matched volunteers were studied. All pulmo-
nary patients had COPD according to American Thoracic Society
guidelines9 and chronic airflow limitation, defined as measured
FEV1  70% of reference FEV1. Furthermore, patients with
COPD had irreversible obstructive airway disease ( 10% im-
provement of FEV1 predicted baseline after 2-agonist inhala-
tion). Patients with COPD were in clinically stable condition and
not having respiratory tract infection or exacerbation of their
disease at least 4 weeks prior to the study. Other exclusion criteria
for the COPD group were concomitant confounding diseases like
malignancies, GI disorders, severe endocrine disorders, CHF, or
recent surgery. The cardiac patients had CHF based on clinical
symptoms according to the Framingham criteria,10 LVEF
 45%, and were in clinically stable condition. All patients with
CHF were controlled at the outpatient clinic of the university
Hospital of Maastricht. The origins of heart failure were idio-
pathic (n  7), ischemic (n  8), valvular disease (n  1), multi-
ple origins (n  6), and miscellaneous (n  3). They were all
receiving extensive medication regiments: angiotensin-converting
enzyme inhibitors (N  24), diuretics (n  24), -blockers
(n  16), and nitrates (n  16). Warfarin was used by 20 patients.
Exclusion criteria for the CHF group were noncardiac disease
with life expectancy  1 year, episodes of heart failure within the
previous 2 months, unstable angina pectoris, scheduled for
percutaneous transluminal coronary angioplasty or coronary ar-
tery bypass grafting, operable valvular disease, kidney failure
(creatinine level  250 mol/L), restrictive cardiomyopathy,
hypertrophic cardiomyopathy, primary pulmonary hypertension,
diabetes mellitus, COPD, psychiatric disorder, or correctable
cause of heart failure. The healthy age-matched control subjects
were volunteers recruited through advertisement in a local
newspaper. They underwent a physical examination by a physi-
cian to ensure that they were free from significant pulmonary or
cardiac disease. Written informed consent was obtained from all
subjects, and the study was approved by the medical ethical
committee of the University Hospital Maastricht (Maastricht, the
Netherlands).
Assessment of Body Composition
FFM was measured by bioelectrical impedance (Xitron 4000b;
Xitron Technologies; San Diego, CA). Resistance was measured
in supine position at the right side as described by Lukaski et al.11
A patient-specific regression equation was used to calculate FFM
in patients with COPD.12 This equation was also used to calculate
the FFM of patients with CHF (validated against the deuterium
dilution method). Body mass index (BMI) was calculated by
dividing whole body weight by the squared body height in order
to correct for differences in body size.13 For the same reason the
FFM index (FFMI) was calculated by dividing the FFM by the
squared body height.13
Cardiopulmonary Function
All patients and control subjects underwent spirometry to
determine the FEV1, with the highest value from at least three
technically acceptable assessments being used. Diffusion capacity
of the lung for carbon monoxide (Dlco) was measured using the
single-breath method (Masterlab; Jaeger; Wurzburg, Germany).
All values obtained were related to a reference value and
expressed as percentage of the predicted value.14 In patients with
COPD as well as in patients with CHF, FEV1 and Dlco were
significantly lower than in control subjects; but as expected, the
FEV1 and the Dlco were markedly lower in patients with COPD
than in patients with CHF (Table 1). In all patients with CHF,
LVEF was measured by M-mode echocardiogram to assess
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cardiac function. In patients with COPD and control subjects,
12-lead ECGs were evaluated, since echocardiography was not
available for logistical reasons. Five patients with COPD showed
abnormalities on the ECG: one with prolonged PR interval, one
with incomplete left bundle branch block, and one with repolar-
ization disturbances inferolaterally. The two others showed left
ventricular hypertrophy, together with conduction disturbances
or left bundle branch block and abnormal ST segments. Six
patients with COPD had normal ECG findings. The other
14 patients with COPD had signs of right ventricular conduction
delay, as there were axis shifts to vertical or right, s in lead I, q in
lead III, (incomplete)-right bundle branch block. Only one
patient had QRS widening of 120 ms. All patients with COPD
had sinus rhythm. In the control group, ECGs were available
from 20 patients: 11 subjects had normal ECG findings,
9 subjects showed right ventricular conduction delay as defined
above, 1 of them together with probable anterior wall myocardial
infarction and 2 of them with inferior wall abnormalities. All
subjects in the control group had sinus rhythm.
Muscle Function
Isokinetic muscle functions (which are described and defined
elsewhere15) of the dominant knee extensor (quadriceps) and
elbow flexor muscles (biceps) were measured using a Biodex
dynamometer (Biodex Corporation; Shirley, NY) or a Cybex II
dynamometer (Cybex; Ronkonkoma, NY). There were no differ-
ences between results obtained using either machine (unpub-
lished results). To assess leg muscle function, subjects were
seated upright on the chair of the dynamometer and provided
with back support. At the level of the chest, pelvis, and thigh,
subjects were restrained with straps. The hip joint was at an angle
between 90° and 100° of flexion during testing. The lever arm
was attached to the distal part of the tibia, and its axis of rotation
was visually aligned with the anatomic axis of flexion of the knee
joint. Subjects were instructed to keep their hands on their thighs
during testing. To assess arm muscle function, subjects sat in
upright on a chair with the shoulder of the dominant arm placed
in 90° abduction. The upper arm was supported and fixed with a
belt in the horizontal plane on an adjustable stand. The ventral
side of the forearm was placed in the frontal plane, and the
handgrip of the lever arm was held by the subjects. The lateral
epicondyle of the humerus was used as the axis of elbow rotation
and was visually aligned with the axis of rotation of the dyna-
mometer. Subjects were instructed to keep their contralateral
hand on their thigh. The isokinetic testing protocols of the
dominant upper and lower extremities consisted of 15 sequential
voluntary maximal contractions at an angular velocity of 90°/s.
Maximal isokinetic strength was defined as the highest peak
torque (in newton-meters [Nm]) in this series of 15.
Fatigue was defined as the proportional decline in peak torque
during 14 successive isokinetic flexions; the peak torques of the
successive contractions were expressed as a percentage of the
highest peak torque. The first contraction was excluded from
analysis because this value is unreliable due to the fact that the
starting maneuver is often submaximal. A linear curve was fitted
through the calculated points. The slope of this curve was used to
calculate the relative change in peak torque as a measure of
muscle fatigue. Series in which the slope was ascending or in
which the curve had an R2  0.209 were excluded. The R2 value
is based on the critical value of the Pearson correlation coefficient
at a one-tailed p value of 0.10 and 13 degrees of freedom. For
comparison of upper- and lower-limb muscle functions, relative
muscle strength and fatigue values were expressed as the per-
centage of mean control values and were calculated separately for
male and female subjects.
Exercise Capacity
All subjects performed an incremental exercise test on an
electrically braked cycle ergometer (Corival 400; Lode; Gro-
ningen, the Netherlands; or Ergo-metrics 900; Ergoline; Frank-
furt, Germany) under supervision of a chest physician or a
cardiologist. Before the start of the test, while seated on the cycle
ergometer, ventilation characteristics at rest were analyzed over a
period of 2 min. During the entire exercise test, expired gases
were analyzed using breath-by-breath analysis through a breath-
ing mask (Oxycon; Jaeger). Heart rate (HR), systolic/diastolic BP,
and percutaneous oxygen saturation were monitored. After 1 min
of unloaded cycling, power was increased by 10 W/min for
patients. For the control subjects, the load was increased with
15 to 25 W/min, so that the length of the exercise test was
comparable for patients and control subjects. None of the
subjects knew the exercise load, and all were encouraged to cycle
at 60 revolutions per minute until exhaustion. Peak oxygen
consumption (V̇o2peak) was measured at the moment of cessa-
tion of the exercise. Peak HR reserve was calculated as
100%  (100  peak HR)/(220  age),16 and peak ventilatory
Table 1—Subject Characteristics*
Characteristics Control Subjects COPD CHF
Subjects (male/female), No. 36 (24/12) 25 (16/9) 25 (17/8)
Age, yr 61 	 5.9 62 	 9.8 63 	 8.0
Length, cm 172 	 9 168 	 7 168 	 9
Weight, kg 78.4 	 11.6 67.8 	 15.1† 71.9 	 11.9
BMI 26.4 	 2.5 23.9 	 4.1† 25.3 	 3.7
FFM, kg 58.7 	 10.8 49.5 	 8.2‡ 50.1 	 9.2‡
FFMI, kg/m2 19.7 	 2.1 17.5 	 2.0‡ 17.6 	 2.1‡
FEV1, % predicted 111 	 17 32 	 11‡ 90 	 22‡§
Dlco, % predicted 112 	 17 48 	 17‡ 73 	 17‡§
Dlco/alveolar volume, % predicted 110 	 17 57 	 20‡ 81 	 18‡§
LVEF, % 29 	 7.2
PASE score 140 	 64 89 	 39‡ 83 	 56‡
*Data are presented as mean 	 SD unless otherwise indicated.
†p  0.01 vs control subjects.
‡p  0.001 vs control subjects.
§p  0.001, COPD vs CHF.
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(minute ventilation [V̇e]) reserve was calculated as
100%  (100  peak V̇e); (FEV1  37.5).16,17
Questionnaire
The daily activity level was assessed through the Physical
Activity Scale for the Elderly (PASE) questionnaire (Dutch
version).18 Questions deal with physical activities during the most
recent 7 days, such as leisure, sports, housework, and gardening.
Statistical Analysis
Data were analyzed with the unpaired Student t test (corrected
for unequal variances, if appropriate), one-way analysis of vari-
ance (with unpaired Student t test as post hoc test), or the
Pearson correlation test, as appropriate.19 For the comparison of
relative strength and upper- and lower-limb muscle function, the
Student t test for paired data was used. Slopes and intercepts of
regression lines were statistically compared using a small-sample
t test, as described by Kleinbaum et al.20 A two-tailed probability
value of  0.05 was considered statistically significant. Data are
shown as mean 	 SD.
Results
Subject Characteristics
Twenty-five patients with COPD (16 men and
9 women), 25 patients with CHF (17 men and
8 women), and 36 healthy control subjects (24 men
and 12 women) participated in this study (Table 1).
There were no differences in gender or age between
the groups. Only patients with COPD had a lower
BMI than control subjects; however, FFMI was
reduced in patients with COPD as well as in patients
with CHF compared to healthy subjects. PASE score
was significantly lower in both patient groups than in
control subjects, but there was no difference be-
tween patients with COPD and patients with CHF.
Incremental Exercise Test
Peak exercise data are shown in Table 2. In
patients, exercise capacity, assessed by bicycle er-
gometry (V̇o2peak), was about 50% of that in control
subjects. The difference between the CHF and
COPD patient groups was small and statistically
insignificant. There was also no difference in
V̇o2peak between patients with COPD with and
without abnormalities on the ECG (not shown).
Ventilation reserve and respiratory quotient (RQ)
were significantly lower in patients with CHF and
patients with COPD compared to control subjects,
but only in patients with COPD was the maximum
ventilation reached and was the peak RQ  1. Only
the control subjects reached their predicted maximal
peak HRs.
Muscle Function
Quadriceps strength (Fig 1, top, A) was lower in
patients with COPD (85 Nm, p  0.001) and pa-
tients with CHF (84 Nm, p  0.001) than in control
subjects (118 Nm). Biceps strength (Fig 1, top, A)
was also lower in patients with COPD (27 Nm,
p  0.001) and patients with CHF (26 Nm, p  0.001)
compared to control subjects (38 Nm). Compared to
control subjects, there was no significant difference
between relative quadriceps and biceps strength in
patients with COPD (78% vs 77%) or in patients with
CHF (72% vs 74%). Quadriceps fatigue (Fig 1, bottom,
B), measured as the proportional decline in peak
torque during 14 successive isokinetic extensions, was
higher in patients with COPD (28%, p  0.001) and
patients with CHF (30%, p  0.002), compared to
healthy subjects (21%). Biceps fatigue (Fig 1, bottom,
B), measured as the proportional decline in peak
torque during 14 successive isokinetic flexions, was also
markedly higher in patients with COPD and patients
with CHF than in control subjects (42% vs 32%,
p  0.007). There were no statistically significant dif-
ferences between patients with COPD and patients
with CHF. Relative fatigue (as the percentage of mean
control values) was also not significantly different be-
tween quadriceps and biceps in patients with COPD
Table 2—Peak Exercise Test Data*
Variables Control Subjects COPD CHF
V̇o2peak, mL/min 2,129 	 659 840 	 261† 1,092 	 271†
V̇o2peak/weight, mL/kg/min 27.1 	 6.5 12.8 	 3.8† 15.3 	 3.3†
V̇co2peak, mL/min 2,636 	 788 840 	 269† 1,234 	 328†‡
V̇co2peak/weight, mL/kg/min 33.8 	 8 13.0 	 4† 17.3 	 4†‡
RQ peak 1.21 	 0.08 0.96 	 0.10† 1.11 	 0.08†§
V̇e peak, % predicted 88 	 26 36 	 13† 48 	 13†‡
V̇e reserve, % 26 	 16  9 	 29† 46 	 20†§
HR peak, beats/min 156 	 13 121 	 17† 113 	 24†
HR reserve, % 0 	 7 24 	 11† 18 	 14†
*Data are presented as mean 	 SD. V̇co2peak  peak carbon monoxide production.
†p  0.001 vs control subjects.
‡p  0.05, COPD vs CHF.
§p  0.001, COPD vs CHF.
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(133 	 32% vs 134 	 34%) or in patients with CHF
(159 	 44% vs 130 	 42%).
Correlations
In each group (COPD, CHF, and control), quad-
riceps and biceps maximal torques correlated
strongly with the FFM, as shown in Figure 2, top left,
A, and bottom left, B, respectively. There were no
differences between the slopes of the individual
subgroup regression lines in upper or lower limbs.
Within each group, quadriceps and biceps strength
correlated significantly with each other (data not
shown). There was no relationship between quadri-
ceps or biceps fatigue and FFM (Fig 2, top right, C,
and bottom right, D, respectively). In addition, there
was no relation between the PASE score and periph-
eral muscle maximal torque or fatigue (data not
shown).
A strong correlation between the V̇o2peak and the
FFM (r  0.843, p  0.001) was found in healthy
control subjects, as shown in Figure 3. A weaker, but
significant, relation was present in patients with COPD
(r  0.563, p  0.005) and patients with CHF
(r  0.484, p  0.017). Positive correlations were also
found between the V̇o2peak and quadriceps strength in
control subjects (r  0.758, p  0.001), patients with
COPD (r  0.498, p  0.018), and patients with CHF
(r  0.749, p  0.001). Quadriceps fatigue did not
correlate with the V̇o2peak in any of the three study
groups. In patients with COPD, the FEV1 (Fig 4, left,
A) or Dlco (not shown) did not correlate with the
V̇o2peak, nor with peak exercise capacity as measured
in watts (data not shown). Similarly, in patients with
CHF, the LVEF (Fig 4, right, B), FEV1, or Dlco (not
shown) did not correlate with the V̇o2peak. In control
subjects, the PASE score correlated with the V̇o2peak
(r  0.400, p  0.032). In patients with COPD, this
relation was absent. In patients with CHF, there was a
correlation between the V̇o2peak and the PASE score
(r  0.645, p  0.001), although this statistical signifi-
cance is based on one outlier (correlation without the
outlier, r  0.428, p  0.053). There were no correla-
tions between the PASE score and LVEF or FEV1 in
patients.
Discussion
In the current study we demonstrate that both
COPD and CHF, two distinct disorders with a
comparably decreased exercise capacity, show strik-
ing similarities with respect to muscle dysfunction,
loss of FFM, and reduced daily activity level when
compared to age-matched healthy control subjects.
We also show that peripheral skeletal muscle weak-
ness is generalized in both disorders with upper and
lower limb muscle function being equally affected.
Furthermore, as in control subjects, the FFM is an
especially strong predictor of exercise capacity, in
contrast to common indexes of primary organ failure
(FEV1 in COPD and LVEF in CHF).
FFM was equally reduced in patients with COPD
and patients with CHF compared to control subjects,
despite a lower BMI in the patients with COPD.
This implies that in patients with CHF, protein
balance may be affected in a manner disproportion-
ate to energy balance, even in weight-stable patients.
Assessment of the FFM instead of body weight
therefore appears important in nutritional assess-
ment, especially in CHF where, in contrast to
COPD, this is not a common procedure. Our results
are in agreement with previous studies showing that
these indexes of the primary organ failure (LVEF
and FEV1) are poor predictors of exercise capacity
in moderate-to-severely diseased patients.2,3,21,22 In-
Figure 1. Muscle strength (expressed as the maximal torque)
and fatigue (expressed as the proportional decline in peak
torque). Top, A: Leg and arm muscle strength. Bottom, B: Leg
and arm muscle fatigue. **p  0.01; ***p  0.001; error bars
represent SEM.
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stead, we found that both in healthy subjects and in
the two patient groups, the quadriceps strength and
the FFM correlated with the V̇o2peak. In all groups,
both control subjects and patients, the same strong
relation between FFM and quadriceps or biceps
strength was found, whereas the FFM did not
correlate with muscle fatigue. It is obvious that
peripheral muscle strength depends largely on the
FFM, thereby explaining why quadriceps strength
correlates with the V̇o2peak. We thus demonstrate
that the FFM is an important determinant of exer-
cise capacity; however, this relation was weaker in
the patient groups than in control subjects, suggest-
ing that other factors are involved in the impaired
exercise capacity and increased muscle fatigue in
patients with COPD and patients with CHF.
Besides muscle wasting, intrinsic muscular abnor-
malities might be involved in skeletal muscle dys-
function and exercise intolerance. We recently re-
viewed intrinsic muscular abnormalities, such as
altered fiber-type distribution and metabolic profile,
in COPD and CHF.23 Although no studies have yet
performed a direct comparison, striking similarities
were also found here, pointing toward a decreased
oxidative capacity. Physical inactivity is frequently
assumed to have a negative or “detraining” effect on
exercise capacity, although this influence has never
been studied in CHF and COPD. In the present
study, daily physical activity level expressed as the
PASE score was approximately 39% lower in patients
than in control subjects, but not different between
patients with COPD and patients with CHF. The
PASE score is an expression of exercise capacity in
healthy control subjects, but it remains unclear from
our data whether it is also true for patients. Since the
observed relationship in patients with CHF between
PASE score and V̇o2peak in this study is based on
one outlier, the possible connection between daily
activity level and the V̇o2peak needs further investi-
gation. Nevertheless, whether PASE score is or is not
a predictor of exercise capacity in patients, it appears
less important than FFM in these severely disabled
Figure 2. Relation between peripheral muscle function and FFM. Top left, A: Leg muscle strength.
Slopes of the regression lines were not different between groups (control subjects, r  0.78, p  0.001;
patients with COPD, r  0.73, p  0.001; patients with CHF, r  0.63, p  0.002). Bottom left, B: Arm
muscle strength. Slopes of the regression lines were not different between groups (control subjects,
r  0.90, p  0.001; patients with COPD, r  0.66, p  0.001; patients with CHF, r  0.75,
p  0.001. Top right, C: Leg muscle fatigue; no relation with FFM. Bottom right, D: Arm muscle
fatigue; no relation with FFM. F  control subjects;  patients with COPD;  patients with
CHF; diagonal lines indicate relation in all subjects.
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patients. We therefore conclude that a reduced daily
activity level may negatively affect exercise capacity
in patients with COPD and patients with CHF, but
its role should not be overinterpreted.
Although muscle weakness in patients with COPD
and patients with CHF has been reported be-
fore,1,8,21 it remains unclear from the literature
whether muscle weakness is generalized and of
similar severity in these disorders. Only few studies
compared strength of different muscle groups, and
some of them suggested that upper-limb muscle
strength is relatively preserved.6–8 It is difficult to
compare these studies because of differences in
methods and target muscles measured. For the
lower limb, the quadriceps muscle is commonly
tested, but for the upper limb, a wide diversity of
muscle groups have been tested, such as the flexor
digitorum (handgrip force), adductor pollicis, biceps,
deltoid, or shoulder abductors. To avoid this prob-
lem in the present study, quadriceps and biceps
strength and fatigue were therefore measured with
the same isokinetic protocol. Neither patients with
COPD nor patients with CHF demonstrated pre-
served upper-limb muscle strength relative to lower-
limb muscle strength. We therefore conclude that
skeletal muscle weakness is generalized in both
disorders.
In this study, pulmonary function was impaired in
patients with CHF, though obviously not to the same
degree as in patients with COPD. This is shown by
the somewhat lower FEV1, but in particular by the
reduced Dlco. Even if corrected for the alveolar
volume, the Dlco was still decreased, which was
also observed by Puri et al,24 whose data suggested
intrinsic abnormalities of the alveolar-capillary mem-
brane. In turn, cardiac function may to some degree
be impaired in patients with COPD. Recently, left
ventricular dysfunction was found in 32% of patients
with COPD in deteriorating condition,25 and in
about 20% of patients in clinically stable condition.26
Since it is known that left ventricular dysfunction is
very unlikely in subjects with a normal ECG find-
ing,27 we evaluated the ECGs of patients with COPD
and healthy control subjects. A substantial part of the
patients with COPD had some degree of right
ventricular conduction delay, which is a common
phenomenon in progressive COPD28 and can also be
a normal electrophysiological variant.29,30 Since the
literature is controversial with respect to the inter-
dependency of left and right ventricular dysfunc-
tion,28,31 some degree of left ventricular dysfunction
cannot be excluded in this study. Five patients with
COPD had abnormal ECG findings, but none of
them had signs of heart failure on physical examina-
tion nor used cardiac medication. The 20 control
subjects showed no ECG abnormalities except right
Figure 3. Relation between exercise capacity and FFM.
F  control subjects (solid diagonal line, r  0.84, p 0.001);
 patients with COPD (dashed line, r  0.56, p  0.005);
 patients with CHF (dotted line, r  0.48, p  0.017). Slopes
of patient regression lines were significantly less steep than that
of the control group, with no difference between patients with
COPD and patients with CHF.
Figure 4. Relation between exercise capacity and primary organ function in patients with COPD ( )
[left, A] and patients with CHF ( ) [right, B]. There were no correlations.
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ventricular conduction delay, which is often seen in
the normal population. The three subjects with
anterior and inferior wall abnormalities also had no
signs of left ventricular dysfunction on physical
examination. Furthermore, the peak ventilatory and
HR reserve values clearly demonstrated that patients
with COPD were primarily limited by their reduced
ventilatory capacity and not by cardiac function,
showing that a potential cardiac impairment is sub-
ordinate to the pulmonary impairment in this group.
Our data also show that patients with CHF were not
ventilatory limited during the exhausting cycling
exercise (their maximum peak HRs were not reached
either, but this is due to the fact that most patients
received -blockers). These results do, however,
emphasize the need to adjust for both cardiac and
pulmonary organ dysfunction in these patient groups
when evaluating the impact of systemic impairment.
In summary, we conclude that skeletal muscle
wasting and weakness are generalized in patients
with COPD and patients with CHF with similar
exercise intolerance. The FFM and daily activity
level are strong predictors of exercise capacity in
healthy control subjects. The FFM is also a signifi-
cant determinant of exercise capacity in patients with
COPD and patients with CHF, in addition to other
yet unidentified systemic factors. This study
strengthens the importance of rehabilitation in both
disorders, and mutual exchange of studies and expe-
rience in treatment modalities including nutrition,
exercise, and anabolic medication.
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